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Induction of autophagy-dependent necroptosis is required for
childhood acute lymphoblastic leukemia cells to overcome
glucocorticoid resistance
Abstract
In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong predictor of poor
outcome in children with acute lymphoblastic leukemia (ALL). Modulation of cell death regulators
represents an attractive strategy for subverting such drug resistance. Here we report complete
resensitization of multidrug-resistant childhood ALL cells to glucocorticoids and other cytotoxic agents
with subcytotoxic concentrations of obatoclax, a putative antagonist of BCL-2 family members. The
reversal of glucocorticoid resistance occurred through rapid activation of autophagy-dependent
necroptosis, which bypassed the block in mitochondrial apoptosis. This effect was associated with
dissociation of the autophagy inducer beclin-1 from the antiapoptotic BCL-2 family member myeloid
cell leukemia sequence 1 (MCL-1) and with a marked decrease in mammalian target of rapamycin
(mTOR) activity. Consistent with a protective role for mTOR in glucocorticoid resistance in childhood
ALL, combination of rapamycin with the glucocorticoid dexamethasone triggered autophagy-dependent
cell death, with characteristic features of necroptosis. Execution of cell death, but not induction of
autophagy, was strictly dependent on expression of receptor-interacting protein (RIP-1) kinase and
cylindromatosis (turban tumor syndrome) (CYLD), two key regulators of necroptosis. Accordingly, both
inhibition of RIP-1 and interference with CYLD restored glucocorticoid resistance completely. Together
with evidence for a chemosensitizing activity of obatoclax in vivo, our data provide a compelling
rationale for clinical translation of this pharmacological approach into treatments for patients with
refractory ALL.
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In	vivo	resistance	to	first-line	chemotherapy,	including	to	glucocorticoids,	is	a	strong	predictor	of	poor	out-
come	in	children	with	acute	lymphoblastic	leukemia	(ALL).	Modulation	of	cell	death	regulators	represents	
an	attractive	strategy	for	subverting	such	drug	resistance.	Here	we	report	complete	resensitization	of	multi-
drug-resistant	childhood	ALL	cells	to	glucocorticoids	and	other	cytotoxic	agents	with	subcytotoxic	concentra-
tions	of	obatoclax,	a	putative	antagonist	of	BCL-2	family	members.	The	reversal	of	glucocorticoid	resistance	
occurred	through	rapid	activation	of	autophagy-dependent	necroptosis,	which	bypassed	the	block	in	mito-
chondrial	apoptosis.	This	effect	was	associated	with	dissociation	of	the	autophagy	inducer	beclin-1	from	the	
antiapoptotic	BCL-2	family	member	myeloid	cell	leukemia	sequence	1	(MCL-1)	and	with	a	marked	decrease	in	
mammalian	target	of	rapamycin	(mTOR)	activity.	Consistent	with	a	protective	role	for	mTOR	in	glucocorti-
coid	resistance	in	childhood	ALL,	combination	of	rapamycin	with	the	glucocorticoid	dexamethasone	triggered	
autophagy-dependent	cell	death,	with	characteristic	features	of	necroptosis.	Execution	of	cell	death,	but	not	
induction	of	autophagy,	was	strictly	dependent	on	expression	of	receptor-interacting	protein	(RIP-1)	kinase	
and	cylindromatosis	(turban	tumor	syndrome)	(CYLD),	two	key	regulators	of	necroptosis.	Accordingly,	both	
inhibition	of	RIP-1	and	interference	with	CYLD	restored	glucocorticoid	resistance	completely.	Together	with	
evidence	for	a	chemosensitizing	activity	of	obatoclax	in	vivo,	our	data	provide	a	compelling	rationale	for	clini-
cal	translation	of	this	pharmacological	approach	into	treatments	for	patients	with	refractory	ALL.
Introduction
Resistance to the initial phase of chemotherapy, in particular 
poor response to glucocorticoids (GCs), is a strong predictor 
of adverse outcome for childhood acute lymphoblastic leuke-
mia (ALL) (1, 2). During the last decade, the cooperative Ber-
lin-Frankfurt-Muenster (BFM) study group has validated an 
effective risk stratification approach, which is based on the 
assessment of the in vivo response to chemotherapy by leuke-
mia-specific quantitative PCR. A group of patients at very high 
risk for relapse (VHR-ALL) can be identified based on persistence 
of minimal residual disease (MRD) (3). Because this is likely to 
reflect de novo resistance to multiple conventional antileukemic 
agents, combination treatment with new agents that modulate 
regulators of cell death represents an attractive approach to 
improve treatment response.
In GC-resistant ALL, the mechanisms underlying defective 
induction of mitochondrial apoptosis are still not understood. 
Increased expression of antiapoptotic myeloid cell leukemia 
sequence 1 (MCL-1) was a predominant feature of the gene expres-
sion signature of GC resistance (4). A bioinformatic screen of drug-
associated signatures identified rapamycin as a sensitizer to GC 
drugs in GC-resistant ALL. The GC-sensitizing effect of rapamycin 
was attributed to a decrease in MCL-1 levels, which was proposed 
to decrease the threshold to apoptotic stimuli by GC drugs (5).
Based on these considerations, we sought to evaluate the poten-
tial of the small molecule obatoclax (GX15-070) for combination 
therapy in refractory childhood ALL. This agent was proposed to 
act as a BCL-2 family antagonist and to disrupt the interaction 
between MCL-1 and its proapoptotic counterparts at cytotoxic 
concentrations (6, 7). Obatoclax was shown to trigger apoptosis 
at concentrations that resulted in disruption of Bak from MCL-1 
and cytochrome c release. However, obatoclax was also cytotoxic 
in cells that are deficient for the apoptosis effectors BAX and BAK, 
and lower concentrations of compound were sufficient to inhibit 
clonogenic growth of AML cells, suggesting the existence of addi-
tional target mechanisms (8). A recommended phase II dose has 
been established for adult patients with hematologic malignancies 
with an acceptable toxicity profile (9, 10), which constitutes the 
basis for further evaluation of obatoclax in pediatric trials.
In the context of defective apoptosis, an alternative cell death 
pathway has been identified that is dependent on macroau-
tophagy (11, 12), a major form of autophagy, in which parts of 
the cytoplasm and intracellular organelles are sequestered within 
characteristic double-membraned or multi-membraned autopha-
gic vacuoles (hereafter referred to as autophagy) (13). Autophagy 
is usually triggered to respond to increased metabolic require-
ments at times of cellular stress. Selected antiapoptotic BCL-2 
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family members can engage in cross-talk between the apoptotic 
and autophagic pathways, as they were show to associate with the 
autophagy regulator beclin-1 (11, 14, 15). When caspase-depen-
dent apoptosis was blocked, a cell death mechanism that required 
autophagy was mediated via the receptor-interacting protein 1 
(RIP-1) (12). RIP-1 is a central kinase that is associated with death 
receptor–induced signalling complexes to modulate the switch 
between survival and death under stress conditions (16). Under 
defective apoptotic conditions, RIP-1 kinase activity was shown 
to mediate an alternative cell death pathway that may represent 
a form of programmed necrosis, also called necroptosis (17, 18). 
Kinase activity of RIP-1 was shown to be dispensable for induc-
tion of cell survival signalling via NF-kB activation or death recep-
tor–mediated apoptosis (17, 19).
Here we show that a subcytotoxic concentration of obatoclax 
effectively restored the response to dexamethasone in GC-resistant 
ALL by triggering a nonapoptotic cell death pathway. Subcytotoxic 
concentrations of obatoclax induced disruption of beclin-1 from 
MCL-1 and the combination of dexamethasone with obatoclax 
was associated with inhibition of mammalian target of rapamycin 
(mTOR) activity, providing a possible mechanism for autophagy 
induction. Obatoclax also conferred clinically relevant broad che-
mosensitization in multidrug-resistant primary cells from VHR-
ALL patients. We provide genetic and pharmacologic evidence to 
show that sensitization to dexamethasone occurs via autophagy-
dependent necroptotic cell death, while sensitization to other cyto-
toxic agents was dependent on apoptosis. In a xenograft model, 
using GC-resistant cells from refractory ALL patients, combina-
tion treatment with dexamethasone and obatoclax reduced leu-
kemia progression significantly. Collectively, our data provide a 
strong rationale for a rapid clinical translation of this approach.
Results
Obatoclax resensitizes GC-resistant ALL to dexamethasone. Because 
MCL-1 has been proposed to act as a central modulator of steroid 
resistance in ALL (4, 5), we first compared the effects of 2 small 
molecules with different selectivity toward MCL-1, ABT-737, 
and obatoclax in GC-resistant ALL cell lines. ABT-737 is a small 
molecule BH3 mimetic with selectivity for BCL-2 and BCL-XL 
(20). Resistance to ABT-737 has been attributed to its inabil-
ity to target MCL-1 (21–23). While both compounds displayed 
strong cytotoxicity across a panel of ALL cell lines (Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI39987DS1), subcytotoxic doses of obatoclax but 
not ABT-737 resensitized GC-resistant cell lines to dexamethasone 
(Figure 1A and Supplemental Figure 1). We confirmed single-agent 
activity for obatoclax in VHR-ALL cells (Supplemental Table 2). 
Low-dose obatoclax restored sensitivity to dexamethasone in 
cells from all 7 poor-prednisone-responder (PPR) VHR-ALL 
patients tested (Figure 1B and Supplemental Figure 2). In con-
trast, no effect on steroid sensitivity using low doses of ABT-737 
or obatoclax was evident in steroid-sensitive cells (Figure 1A). 
Unexpectedly, the pan-caspase inhibitor zVAD.fmk did not inter-
fere with the steroid-sensitizing effect of obatoclax in GC-resis-
tant cells (Figure 2A), whereas zVAD.fmk blocked the cytotoxic 
effect of dexamethasone with or without obatoclax in GC-sensi-
Figure 1
Obatoclax resensitizes GC-resistant ALL cells to dexamethasone. Combination experiments were performed with subcytotoxic concentrations 
(10% IC50) of obatoclax (oba) or ABT-737 and 1 μM dexamethasone (DEX), and values were normalized to cells treated with vehicle control. 
(A) ALL cell lines were treated for 72 hours as indicated. Cell viability was determined by the MTT assay. (B) Primary ALL cells from 7 PPR 
patients with VHR-ALL and 3 prednisone-good-responder (PGR) patients were treated as indicated for 72 hours. Cell viability was assessed by 
flow cytometry using 7AAD. ***P < 0.05.
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tive cells and in control experiments when cell death was induced 
by staurosporine (STS). Using clonogenic assays, we confirmed 
that obatoclax was equally effective in ALL cells that are devoid 
of caspase-9 or BAX and BAK, when compared with parental cell 
lines (Figure 2B and Supplemental Figure 3). Furthermore, obato-
clax-mediated GC sensitization resulted in neither the restoration 
of mitochondrial membrane depolarization (Figure 2C) nor an 
increase in cytochrome c release when compared with the effect 
Figure 2
Obatoclax resensitizes GC-resistant ALL cells to dexamethasone without activation of mitochondrial apoptosis. (A) ALL cells were treated as indicated 
for 48 hours, for controls STS or zVAD.fmk (80 nM) was used, and cell viability was assessed with the MTT assay. 697 cells served as GC-sensitive 
control. (B) Jurkat CASP9–/– and BAX–/–BAK–/– cells were treated for 72 hours as indicated, and clonogenic survival was assessed after incubation 
in methylcellulose for 7 days. (C) Percentages of cells with JC-1 monomers, corresponding to a loss of the mitochondrial potential, are shown for 
GC-resistant CEM-C1 and GC-sensitive CEM-C7 cells and in samples from PGR and PPR patients after treatment as indicated for 16 hours. (D) 
Cytochrome c release was induced in steroid-sensitive RS4;11 cells but not in the resistant CEM-C1 cell line upon treatment with dexamethasone or 
dexamethasone and obatoclax. STS was used as positive control. Cytochrome c release was detected by flow cytometry. ***P < 0.05.
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Figure 3
Obatoclax induces autophagy in GC-resistant ALL cells. (A) After transient transfection with GFP-LC3, Jurkat cells were treated for 4 hours as 
indicated. The characteristic punctuate staining pattern indicative of autophagosome formation was detected by confocal microscopy in cells 
treated with dexamethasone and obatoclax or rapamycin (rapa). Scale bar: 10 μm. (B) Quantitation of autophagosome-positive cells. The data 
represent mean ± SD of 2 independent experiments, counting 200 cells each. (C) Detection of endogenous LC3-II by Western blot analysis. 
Jurkat cells were treated with obatoclax and dexamethasone for the indicated time points in the presence or absence of 3-MA and after 24 hours 
of treatment as indicated. (D) Inhibition of autophagy by 3-MA or bafilomycin impaired sensitization to dexamethasone by 10 nM rapamycin or 
obatoclax (10% IC50). Cell viability was assessed by MTT. (E) Treatment with obatoclax and dexamethasone inhibited clonogenic survival of 
Jurkat cells. 3-MA rescued GC-resistant cells from cell death induced by combination treatment. Cells were treated for 72 hours with compounds, 
and clonogenic survival in methylcellulose was assessed after washing and incubation for 7 days. (F) Downregulation of beclin-1 or ATG7 using 
siRNA (si) impaired the resensitization of Jurkat cells to dexamethasone by obatoclax or rapamycin compared with scrambled (scr) controls. Cell 
viability was assessed by MTT. Efficiency of downregulation at 48 hours was analyzed by Western analysis. (G) Downregulation of beclin-1 and 
ATG7 in Jurkat cells protected cells from obatoclax- and dexamethasone-induced cell death in the clonogenic assay. ***P < 0.05.
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of dexamethasone in GC-sensitive cells (Figure 2D). In line with 
these findings, caspase-9 was not activated and caspase-3 was 
only marginally activated in steroid-resistant cells treated with 
the combination of obatoclax and dexamethasone (Supplemental 
Figure 4). Collectively, our results indicate that the combination 
of obatoclax and dexamethasone triggers a cell death mechanism 
that is independent of the apoptotic function of caspases in ste-
roid-resistant leukemia.
Induction of autophagy is essential for steroid sensitization in ALL cells. 
Because an autophagy-dependent cell death pathway has been 
Figure 4
Obatoclax and rapamycin induce autophagic cell death in Bax–/–Bak–/– MEFs. (A) Bax–/–Bak–/– MEFs transiently expressing the autophagy marker 
GFP-LC3 were treated with vehicle, obatoclax (100 nM), or rapamycin (10 nM) for 4 hours. Autophagosome formation was monitored by confocal 
microscopy. Scale bar: 20 μm. (B) Quantitation of autophagosome-positive cells. The data represent mean ± SD of 2 independent experiments, 
counting 200 cells each. (C) Treatment of Bax–/–Bak–/– MEFs with obatoclax induced generation of endogenous LC3-II as detected by Western analy-
sis, an effect which was blocked by 3-MA treatment. (D) WT or Bax–/–Bak–/– (DKO) MEFs were incubated for 48 hours with obatoclax or ABT-737, and 
cell viability assessed by the MTT assay. (E) Inhibition of autophagy by 3-MA rescued Bax–/–Bak–/– MEFs but not WT MEFs from cell death induced 
by 48 hour exposure to obatoclax or rapamycin. (F) Downregulation of beclin-1 rescued Bax–/–Bak–/– MEFs but not WT MEFs from cell death induced 
by obatoclax as evaluated by the MTT assay. Efficiency of downregulation was determined by Western blot analysis. (G) Downregulation of ATG7 
rendered Bax–/–Bak–/– MEFs but not WT MEFs resistant to obatoclax treatment. Efficiency of downregulation was assessed by Western blotting.
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described in cell line models in which apoptosis is prevented (11, 24), 
we evaluated next whether autophagy was required for GC sensitiza-
tion by obatoclax. Indeed, autophagosome formation was evident in 
GC-resistant cells after 4 hours of exposure to low-dose obatoclax 
in combination with dexamethasone, which correlated with genera-
tion of endogenous LC3-II (Figure 3, A–C). Because rapamycin is 
known to be an inducer of autophagy (25), we asked whether the 
GC-sensitizing effect reported recently for rapamycin (5) could also 
be dependent on autophagy. As we expected, steroid sensitization by 
rapamycin was associated with hyperautophagic features (Figure 3, 
A and B). Obatoclax or rapamycin alone only marginally induced 
autophagosome formation and generation of LC3-II (Figure 3, A–C). 
Preincubation with the autophagy inhibitor 3-methyladenine (3-MA) 
abolished autophagosome formation, generation of LC3-II, and GC 
resensitization by obatoclax and rapamycin (Figure 3, B–D). Both 
bafilomycin, a late-stage inhibitor of autophagolysosome formation 
(25), and downregulation of the essential autophagy genes beclin-1 
(BECN1) and ATG-7 (ATG7) by RNA interference blocked GC-resen-
sitization by obatoclax and rapamycin (Figure 3, D–G). These results 
were confirmed in an independent cell line (Supplemental Figure 5). 
Clonogenic assays demonstrate that both addition of 3-MA and 
downregulation of beclin-1 prevented the cytotoxic effect of low-
dose obatoclax combined with dexamethasone, since clonogenic 
growth was comparable to that in untreated controls (Figure 3, 
F and G). In GC-sensitive ALL cells, inhibition of autophagy by 3-MA 
only marginally restored GC resistance, despite small amounts of 
detectable LC3 lipidation (Supplemental Figure 6). These findings 
implicate autophagy as part of a common mechanism for GC resen-
sitization by obatoclax and rapamycin.
To determine whether obatoclax triggers the autophagy path-
way as a general response to blockade of mitochondrial apoptosis, 
we studied the drug’s effects on Bax–/–Bak–/– mouse embryo fibro-
blasts (MEFs), which exhibit resistance to a broad range of apop-
totic stimuli (26). Like rapamycin, obatoclax induced autophagy in 
Bax–/–Bak–/– MEFs (Figure 4, A–C), as reflected by autophagosome 
formation (Figure 4, A and B) and generation of LC3-II (Figure 4C). 
Obatoclax was cytotoxic to WT and Bax–/–Bak–/– MEFs, whereas 
ABT-737’s activity was restricted to WT MEFs (Figure 4D). The 
death response was blocked by 3-MA (Figure 4E) and downregu-
lation of beclin-1 or ATG-7 (Figure 4, F and G). Taken together, 
these results indicate that the cytotoxic effects of obatoclax and 
rapamycin derive from induction of autophagy when mitochon-
drial apoptosis is blocked.
Modulation of the GC response by obatoclax is associated with inhibition of 
mTOR. A key regulator of cell fate decisions, including regulation of 
autophagy, is the kinase mTOR (27). Inhibition of mTOR by rapa-
mycin resensitizes steroid-resistant ALL cells to dexamethasone (5), 
but the role of autophagy has not been investigated in this study. 
Since dexamethasone has been shown to inhibit mTOR in other cel-
lular systems (28), we investigated the effect of dexamethasone and 
obatoclax treatment on mTOR activity. Alone dexamethasone slight-
ly induced a decrease of S6 protein phosphorylation (Figure 5A). 
Treatment with obatoclax or rapamycin and dexamethasone resulted 
in a sharp decrease of the phosphorylation of the mTOR targets S6 
protein and 4EB-P1 (Figure 5A). Interestingly, rapamycin but not 
obatoclax, either alone or in combination with dexamethasone, 
induced dephosphorylation of AKT at Ser473 (Figure 5A). Combina-
tion of obatoclax or rapamycin and dexamethasone also resulted in 
Figure 5
Combination treatment with dexamethasone and obatoclax leads to inhibition of mTOR. (A) Jurkat cells were treated for 6 hours as indicated, 
and phosphorylation of the mTOR targets, S6 protein and 4EB-P1, was assessed. Combination of dexamethasone with either obatoclax or 
rapamycin resulted in inhibition of mTOR activity (top panel). Rapamycin alone and in combination with dexamethasone, but not obatoclax alone 
or with dexamethasone, decreased the phosphorylation of AKT at Ser473 in Jurkat and CEM-C1 cells (bottom panel). (B) In primary cells from 
PPR patients with VHR-ALL, treatment with dexamethasone and obatoclax or rapamycin resulted in a decrease of S6 protein phosphorylation. 
In contrast, in cells from prednisone-good-responder patients, S6 protein was not dephosphorylated after combination treatment.
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dephosphorylation of S6 protein in primary ALL cells from steroid-
resistant high risk ALL patients (Figure 5B, left). In contrast, cells 
from steroid-sensitive patients did not show dephosphorylation 
of S6 protein after treatment with obatoclax and dexamethasone 
(Figure 5B, right). Our experiments suggest that in the context of GC 
resistance, exposure to dexamethasone could cooperate with expo-
sure to obatoclax to decrease mTOR activity. This finding will be 
exploited to develop correlative markers of biological response to in 
vivo treatment, for example, using phospho-flow cytometry to moni-
tor the phosphorylation status of S6 protein in leukemia cells.
Obatoclax disrupts a complex between beclin-1 and MCL-1. The anti-
apoptotic BCL-2 family member MCL-1 was proposed to act as 
a modulator of GC resistance (5). Because the autophagy regula-
tor beclin-1 was described to interact with antiapoptotic BCL-2 
family members, including MCL-1 (11, 14, 15), we next tested the 
effect of obatoclax on the interaction of beclin-1 with MCL-1. 
Subcytotoxic concentrations of obatoclax resulted in a markedly 
decreased detection of MCL-1 that coimmunoprecipitated with 
overexpressed, epitope-tagged beclin-1 in 293T cells (Figure 6A). 
We confirmed this result by performing coimmunoprecipita-
tion experiments of endogenously expressed proteins in ALL cells 
(Figure 6B). Again, in presence of subcytotoxic concentrations of 
obatoclax, less beclin-1 was shown to coimmunoprecipitate with 
MCL-1, and inversely, less MCL-1 was pulled down together with 
beclin-1. Obatoclax did not modify interactions between beclin-1 
and BCL-2. Interestingly, incubation with rapamycin or ABT-737 
did not affect the complex between beclin-1 and MCL-1. As expect-
ed from the reported MCL-1 interaction spectrum (29, 30), BIM 
was detectable by coimmunoprecipitation from steroid-resistant 
ALL cells, but binding of BIM to MCL-1 was not altered by treat-
ment with low-dose obatoclax. The BH3-only protein NOXA, 
which was shown to interact preferentially with MCL-1, did not 
bind to MCL-1 in this experimental setting (Figure 6B).
Since MCL-1 can be subjected to a high protein turnover (31), we eval-
uated the effect of combination treatment with obatoclax and dexa-
methasone on MCL-1 protein levels. In the presence of cycloheximide, 
MCL-1 levels rapidly decreased after 45 minutes of incubation, inde-
pendent of the presence of obatoclax and dexamethasone (Figure 6C). 
Absence of proapoptotic BIM induction by dexamethasone has been 
described in selected cases of steroid-resistant ALL (32). We did not 
detect any changes in BIM expression levels to correlate with the 
restored response to dexamethasone in combination with obatoclax 
Figure 6
Obatoclax induces disruption of a complex of MCL-1 and beclin-1. (A) FLAG-tagged beclin-1 was overexpressed in 293T cells, and MCL-1 
immunoprecipitates were analyzed for the presence of beclin-1, with or without obatoclax treatment for 3 hours. (B) Jurkat cells were treated 
with 100 nM obatoclax, 30 nM ABT-737, or 10 nM rapamycin for 3 hours, and MCL-1 or beclin-1 immunoprecipitates were analyzed for the pres-
ence of proteins as indicated. Low-dose obatoclax disrupted the interaction between beclin-1 and MCL-1, while interactions between BCL2 and 
beclin-1 were unaffected. Likewise, ABT-737 or rapamycin did not affect complexes between beclin-1 and MCL-1 or BCL2. (C) MCL-1 levels 
were assessed after treatment with vehicle or the combination of dexamethasone and obatoclax at indicated time points, with or without cyclo-
heximide (CHX). Western blot analyses revealed that MCL-1 levels were unaffected by combination treatment. (D) BIM induction was assessed 
by Western blot in steroid-resistant (Jurkat, VHR-01, and VHR-02) and steroid-sensitive (RS4;11, 697, SR-01, and SR-02) cell lines and primary 
cells treated with DEX (1 μM), obatoclax (100 nM), or the combination for 24 hours.
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Figure 7
RIP-1 kinase activity is essential for obatoclax-mediated GC sensitization. (A) Electron microscopy images reveal features of necroptotic cell 
death after treatment for 72 hours with obatoclax and dexamethasone. No condensed chromatin was detectable, while Trail treatment induces 
condensed apoptotic nuclei (top panel) (original magnification, ×7,100). Cells treated with obatoclax and dexamethasone exhibited disintegrated 
plasma membranes, which was recapitulated by Na-azide. Trail treatment leaved membranes intact (bottom panel) (original magnification, 
×5,400). (B) A more detailed view of the same experiment. An autophagosome formation with characteristic double membrane structures was 
detected in the cytoplasm. The plasma membrane was disrupted in cells treated with obatoclax and dexamethasone. N, nucleus; C, cytoplasm; 
A, autophagosome; PM, plasma membrane (original magnification, ×15,000). (C) In steroid-resistant (CEM-C1 and Jurkat) and steroid-sensitive 
(697) cells treated for 72 hours with dexamethasone (1 μM) and obatoclax (10% IC50), with or without the necroptosis inhibitor nec-1 (300 nM), 
nec-1 restored steroid resistance as assessed by the MTT assay. (D) Jurkat RIP1–/– cells were less sensitive to the double treatment for 72 hours 
with dexamethasone (1 mM) and obatoclax (10% IC50) compared with WT Jurkat cells. Cell viability was assessed by the MTT assay. (E) 
Downregulation of CYLD rescued Jurkat cells from cell death induced by combination treatment for 72 hours with dexamethasone (1 μM) and 
obatoclax (10% IC50). Efficiency of downregulation was assessed by Western blot analysis after 48 hours. (F) LC3-II generation occurred in 
Jurkat RIP1–/– cells and in WT cells after 8 hours of treatment with dexamethasone and obatoclax. (G) Treatment with nec-1 did not inhibit LC3-II 
generation induced by treatment with obatoclax and dexamethasone in Jurkat cells. ***P < 0.05.
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in GC-resistant ALL cells (Figure 6D). Interestingly, induction of BIM 
was not detectable consistently in steroid-sensitive cells (Figure 6D). 
While in RS4;11 cells, BIM was readily induced by dexamethasone, 
neither 697 cells nor primary ALL cell samples from steroid-resistant 
patients showed induction of this proapoptotic BH3-only protein 
after dexamethasone treatment (Figure 6D). In cells from steroid 
sensitive patients, a small increase in the BIM-L and BIM-S but not 
BIM-EL isoforms was detectable. These data indicate that steroid 
resensitization by obatoclax is not due to induction of BIM.
To obtain further insight into the role of MCL-1 for the mecha-
nism of action of obatoclax, we modulated MCL-1 expression 
using RNA interference. A reduction of MCL-1 protein levels 
resulted in partial resensitization to dexamethasone but, surpris-
ingly, prevented any additional chemosensitization by the combi-
nation with obatoclax (Supplemental Results and Supplemental 
Figure 7). Partial resensitization to dexamethasone was mediated 
via induction of apoptosis, which was blocked using the pan-cas-
pase inhibitor zVAD.fmk. Inhibition of autophagy with 3-MA did 
not affect the resensitization effect of MCL-1 knockdown to dexa-
methasone, even in presence of obatoclax. Instead, caspase-9 acti-
vation was detected, which correlated with a caspase-dependent 
decrease of beclin-1. Thus, it is possible that induction of apopto-
sis overrides induction of autophagy when MCL-1 is downregu-
lated, which limits the interpretation of these experiments. Taken 
together, our data indicate that disruption of the beclin–MCL-1 
interaction is part of the mechanism triggered by obatoclax and 
suggest an involvement of MCL-1 in the regulation of an autoph-
agy-dependent cell death pathway, in addition to its role as anti-
apoptotic regulator in leukemia cells.
Combination of obatoclax and dexamethasone triggers RIP-1 kinase–
dependent necroptosis in GC-resistant ALL. To better assess the nature 
of cell death occurring with obatoclax and dexamethasone, we pro-
ceeded with imaging by transmission electron microscopy. Indeed, 
autophagosome formation was evident after treatment with oba-
toclax and dexamethasone, which was completely inhibited by 
incubation with 3-MA (Figure 7, A and B). Cells displayed features 
consistent with a nonapoptotic cell death mechanism after expo-
sure to obatoclax and dexamethasone. Condensation of chromatin, 
a hallmark of classical apoptosis, was incomplete (Figure 7A, top 
row), which contrasts with the marked chromatin condensation 
after treatment with TRAIL, which induces death receptor–depen-
dent apoptosis in ALL cells (33). A characteristic feature of dead cells 
was the disintegration of the plasma membrane (Figure 7B), which 
is a hallmark of necroptosis (34). Increasing evidence suggests that 
a programmed necrotic cell death pathway can be triggered in the 
context of impaired apoptotic effectors, and this is dependent on 
RIP-1 kinase activity (12, 17). RIP-1 functions at the intersection of 
cell survival and cell death signalling (35, 36). Therefore, we test-
ed whether inhibition of RIP-1 with necrostatin-1 (nec-1; ref. 17) 
would interfere with steroid sensitization by obatoclax. Indeed, ste-
roid-resistant ALL cells treated with nec-1 were refractory to oba-
toclax-induced dexamethasone resensitization (Figure 7C). Nec-1 
also reduced the cytotoxic response to dexamethasone, alone or in 
combination with low-dose obatoclax in steroid-sensitive ALL cells 
(Figure 7C). Interestingly, nec-1 inhibited induction of BIM in ste-
roid-sensitive cells that showed BIM induction after dexamethasone 
(Supplemental Figure 8). Consistent with a central role for RIP-1 for 
the response to GC drugs, RIP-1–deficient ALL cells (37) were resis-
tant to obatoclax-mediated GC resensitization (Figure 7D).
The deubiquitinase cylindromatosis (turban tumor syndrome) 
(CYLD) is a direct regulator of RIP-1 kinase activity (38). Knocking 
down CYLD expression showed that CYLD is required for RIP-1–
dependent cell death induction by combination of dexamethasone 
and obatoclax (Figure 7E). Our results are consistent with the cur-
rent model, which proposes that the deubiquinated form of RIP-1 
is mediating cell death signals (35). An important finding is that 
induction of autophagy could be detected early, within 4 hours 
of treatment, and that generation of LC3-II was neither inhibited 
in RIP-1–deficient ALL cells (Figure 7F) nor in nec-1–treated ALL 
cells (Figure 7G). Taken together, these results demonstrate that 
the combination of obatoclax and dexamethasone triggers a non-
apoptotic cell death pathway, which shares the central features of 
necroptosis, including the characteristic morphology of cell death 
shown by electron microscopy, and a strict dependence on RIP-1 
kinase activity and RIP-1 deubiquitinase CYLD. Moreover, our 
data indicate that the autophagic process is triggered upstream of 
RIP-1 and does not occur as a consequence of necroptosis.
Obatoclax is a broad chemosensitizer in multidrug-resistant primary ALL 
cells, but activation of autophagy-dependent cell death is specific to the com-
bination with dexamethasone. To validate our results in primary cells, 
we tested pretreatment samples from PPR patients with precursor 
B cell ALL, who were further characterized by the molecular persis-
tence of leukemic cells under intensified conventional multiagent 
chemotherapeutic treatment and predicted to have a very high risk 
of relapse based on their poor in vivo response to chemotherapy 
(Supplemental Table 2). Indeed, low-dose obatoclax resensitized 
GC-resistant ALL cells to dexamethasone in mesenchymal stroma 
cell (MSC) cocultures, which was completely abolished using 3-MA, 
implicating autophagy as an essential mechanism in primary 
refractory ALL cells also (Figure 8A). At this dosage, obatoclax alone 
induces less than 5% cell death. Importantly, 3-MA did not interfere 
with the cytotoxic effect of treatment with dexamethasone, alone or 
combined with obatoclax, on primary ALL cells from GC-sensitive 
patients (Figure 8A), indicating that autophagy was not required 
for the death response to GC drugs in GC-sensitive cells. Consistent 
with our results in ALL cell lines, nec-1 abolished the GC-sensitiz-
ing activity of combination treatment in steroid-resistant primary 
Figure 8
Obatoclax displays a strong chemosensitizing activity in multidrug-resis-
tant primary ALL cells from poor risk patients. (A) Primary ALL cells from 
5 PPR patients and 3 prednisone-good-responder patients were cocul-
tured with hTERT-immortalized bone marrow stroma cells and treated 
with either dexamethasone (1 μM) alone or in combination with obatoclax 
(10% IC50) in the presence or absence of 3-MA, nec-1, or zVAD.fmk for 
72 hours. Cell viability was assessed by 7AAD staining and flow cytom-
etry. Data are shown as mean ± SD of 2 independent experiments. In 
combination experiments, values were normalized to cells treated with 
compounds and/or inhibitors alone at indicated dose. (B) Primary ALL 
cells from 4 VHR, 1 high risk (HR), and 3 standard risk (SR) patients 
were cocultured with hTERT-immortalized bone marrow stroma cells and 
treated with either daunorubicin, vincristine, or cytarabine (araC) alone 
or in combination with obatoclax (10% IC50) in the presence or absence 
of 3-MA, nec-1, or zVAD.fmk for 72 hours. Cell viability was assessed 
by 7AAD staining and flow cytometry. Data are shown as mean ± SD 
of 2 independent experiments. ***P < 0.05 (A and B). (C) Percentage of 
event-free survival (pEFS) of NSG mice after xenotransplantation with 
primary cells from 2 PPR patients with VHR-ALL (VHR-02, n = 8; patient 
VHR-01, n = 6; Supplemental Table 2) and treatment for 3 weeks with 
either vehicle, dexamethasone, obatoclax, or the combination. P < 0.02 
for dexamethasone and obatoclax versus vehicle, dexamethasone, or 
obatoclax alone for both xenograft experiments.
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VHR-ALL cells. In contrast, blocking caspases with zVAD.fmk did 
not inhibit steroid resensitization in primary GC-resistant ALL 
cells, while the response to dexamethasone was inhibited by zVAD.
fmk treatment in cells from steroid-sensitive ALL patients.
Current treatment protocols include a steroid window followed 
by multidrug chemotherapy, including cytotoxic agents such as 
daunorubicin, vincristine, and cytarabine. Low-dose obatoclax 
resensitized primary refractory ALL cells to all 3 drugs, while the 
sensitivity of cells from sensitive patients was not increased fur-
ther. Interestingly, 3-MA did not restore resistance to these cyto-
toxic agents, indicating that induction of autophagy after treat-
ment with obatoclax is specific for GC resensitization (Figure 8B). 
In contrast, blocking caspases using zVAD.fmk completely inhib-
ited the resensitizing effect of low-dose obatoclax in combinations 
with daunorubicin, vincristine, and cytarabine, both in cells from 
very high risk and from standard risk patients. These results sup-
port the notion that autophagy-dependent necroptosis is specifi-
cally triggered with GCs in a GC-resistant context. Moreover, oba-
toclax could serve as a chemosensitizer for established multidrug 
regimens for ALL treatment, given its broad potential to restore 
the apoptotic response with non-GC antileukemic drugs.
Combination of obatoclax and dexamethasone is effective in a leukemia 
xenograft model, using cells from refractory ALL patients. To test the in 
vivo efficacy of obatoclax in GC resensitization, we transplanted 
primary ALL cells from 2 VHR-PPR patients into NOD/SCID/
IL2rγnull (NSG) mice (39). When 1% human leukemic cells were 
detected in mouse peripheral blood, we treated mouse cohorts 
with vehicle, obatoclax (5 mg/kg/d), dexamethasone (5 μg/kg/d), 
or both for 3 weeks. In vehicle-treated animals, progression to leu-
kemia (>10% peripheral blasts) was observed in a median time of 11 
weeks for animals xenografted with cells from patient VHR-02 and 
1 week for animals xenografted with cells from patient VHR-01. All 
mice xenografted with cells from patient VHR-02 and treated with 
single-agent dexamethasone or obatoclax had to be sacrificed due 
to leukemia progression, while only 2 out of 8 animals treated with 
the combination of obatoclax and dexamethasone progressed to 
leukemia over the 50-week observation period. A significant delay 
in leukemia progression was achieved by combination treatment 
with dexamethasone and obatoclax when cells from VHR-01 were 
used (P < 0.02 for combination treatment versus vehicle or single 
agent treatment). This patient showed the recurrent translocation 
t(17;19)(q22;p13), which is virtually always associated with early 
relapse (40) (Figure 8C). This result suggests that GC sensitization 
of VHR-PPR ALL cells can be achieved in vivo, providing a strong 
rationale to explore the therapeutic potential of combined dexa-
methasone and obatoclax clinically.
Discussion
Here we describe a pharmacological approach that we believe to 
be new to specifically bypass the apoptotic blockade to chemo-
therapy in multidrug-resistant ALL. Subcytotoxic concentrations 
of the BCL-2 antagonist obatoclax restored the response to dexa-
methasone by inducing a nonapoptotic cell death pathway. The 
activation of autophagy-dependent cell death in cells that are 
resistant to the apoptotic stimuli by dexamethasone is reminis-
cent of observations that were reported using experimental sys-
tems with defined genetic defects of key regulators of the intrinsic 
and extrinsic apoptotic response. In Bax–/–Bak–/– MEFs and BCL-2– 
overexpressing MEFs, cell death triggered by etoposide or STS was 
dependent on autophagy genes beclin-1 and ATG-5 (11). As also 
reported by others (6, 8), obatoclax was cytotoxic for Bax–/–Bak–/– 
cell lines, which we demonstrate to be critically dependent on the 
autophagy pathway. Similarly, genetic or pharmacologic inter-
ference with caspase 8 or death receptor signalling can result in 
autophagy-dependent cell death with necroptotic features (12, 18, 
41). In lymphoid cells, this may constitute an alternative mecha-
nism to control abnormal cellular proliferation in the absence of a 
normal apoptotic response. In activated T cells from mice with cas-
pase-8 or FADD deficiency, autophagic signalling was required to 
induce RIP-1–dependent necroptotic cell death (41). We here show 
that this mechanism of cell death can be activated in GC-resistant 
leukemia to restore the response to dexamethasone.
Autophagy has been recognized as an important regulatory 
mechanism of cell fate decisions. While it is clear that autophagy 
can have a protective function at times of cellular stress, the contri-
bution of autophagy to the execution of programmed cell death is 
a subject of controversy (13). Our data demonstrate that autopha-
gic signalling is an integral part of the cell death mechanism when 
the response to dexamethasone is restored with obatoclax or rapa-
mycin. Both inhibitors that interfere early (3-MA) or late (bafilo-
mycin) with the autophagic process and knockdown of genes that 
are essential for autophagy, BECN1 and ATG7, prevented resensiti-
zation to dexamethasone completely. Combination of dexametha-
sone and obatoclax inhibited clonogenic growth of GC-resistant 
ALL cells, and electron microscopy imaging unequivocally showed 
rapid induction of necrotic cell death with autophagic features. 
There is clear evidence that in cancer, autophagy is not necessarily 
a protective feature. For example, BECN1 was shown to act as a 
haploinsufficient tumor suppressor gene (42, 43), with increased 
frequency of spontaneous neoplasia, including lymphomas in 
beclin-1–haploinsufficient mice. The genes that are essential for 
the autophagic machinery are highly conserved and required in 
several autophagy-dependent cellular processes (44). Several stud-
ies link autophagy genes to programmed cell death. In the central 
nervous system for example, ATG7 deficiency protected neurons 
from caspase-dependent and caspase-independent cell death 
after hypoxic/ischemic brain injury (45). In human glioblastoma, 
knockdown of the autophagy genes ATG1 or ATG5 prevented 
the cytotoxic effect of cannabinoids, which induce autophagy-
dependent cell death via an mTORC1-dependent pathway (46). 
Autophagy was also shown to regulate programmed cell death 
during development. The steroid hormone ecdysone triggered 
autophagy-dependent cell death during morphogenesis of sali-
vary glands from the larval stage to the adult stage in Drosophila. 
This cell death pathway was independent of caspase activity (47), 
providing compelling evidence for the modulation of an autopha-
gic cell death pathway via steroid hormone signalling in normal 
development. Similarly, autophagy is required for programmed 
cell death in the midgut during Drosophila metamorphosis, which 
provides additional evidence for specific regulation of cell death by 
autophagy, even in presence of an intact apoptotic machinery (48). 
Combination treatment of obatoclax with GC drugs but not with 
other cytotoxic agents induced autophagy-dependent cell death in 
resistant ALL. This raises the question of whether autophagy is also 
required for the effect of dexamethasone in GC-sensitive ALL. A 
recent report described increased autophagy after dexamethasone 
treatment in GC-sensitive ALL cell lines, but cell death was associ-
ated with apoptotic features and knockdown of beclin-1 resulted 
only in partial rescue of this effect (49). We also observed a partial 
reduction of dexamethasone cytotoxicity using 3-MA (Supplemen-
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tal Figure 6) or nec-1 (Figure 7C) in a subset of GC-sensitive cell 
lines. We could, however, not detect an effect of 3-MA in primary 
ALL cells, in which caspase-dependent cell death prevailed. Our 
results identify autophagy as an early and limiting step to steroid 
sensitization by obatoclax in GC-resistant cells and underscore the 
importance of understanding the cellular context when designing 
strategies to target autophagy for cancer treatment.
There is clear evidence for hyperactivation of AKT (50) and 
mTOR (5) in GC-resistant ALL. Because mTOR is implicated in 
the control of autophagy in different settings (27), hyperactive 
AKT-mTOR signalling could prevent induction of autophagy in 
resistant disease. We hypothesized that GC-resistant ALL cells 
could therefore be primed for mTOR-controled autophagy. Con-
sistent with this idea, we found that induction of autophagic cell 
death by the combination of dexamethasone and obatoclax result-
ed in marked reduction in phosphorylation of the mTOR target 
S6 protein in resistant cells. The mechanisms by which obatoclax 
or rapamycin potentiate the effect of dexamethasone on mTOR 
appear to be different. Indeed combination of dexamethasone 
with rapamycin, but not with obatoclax, resulted in a marked 
decrease in phosphorylation of AKT on Ser473, consistent with 
recent finding showing that mTOR can also act upstream of AKT 
(51). Modulation of mTOR target phosphorylation was only seen 
when obatoclax was combined with dexamethasone, but not with 
other cytotoxic agents, suggesting that dexamethasone exposure 
contributes to inhibition of mTOR. Indeed, exposure to dexa-
methasone was reported to be associated with repression of mTOR 
signalling in myoblast cell lines and lymphoid cells (28, 52). The 
importance of mTOR for the control of autophagy is also under-
scored by the results of a comprehensive screen using a chemical 
compound library in order to identify new pharmacologic induc-
ers of autophagy, in which proautophagic activity of candidate 
molecules was always associated with decreased phosphorylation 
of mTOR targets (53). Extensive studies will be required to dissect 
the primary signalling events triggered by the combination of oba-
toclax and dexamethasone, as they may provide important clues 
about the mechanisms of drug resistance in ALL.
GC resistance does not appear to be associated with genetic or 
functional defects of the GC receptor in ALL (54, 55). Dexametha-
sone was proposed to induce apoptosis by increasing the levels of 
the BH3-only proapoptotic protein BIM, which were markedly 
reduced in selected cases of GC-resistant ALL (32). However, in most 
cases tested, we could not detect induction of BIM by dexametha-
sone in GC-sensitive cell lines and primary ALL cells. Furthermore, 
we did not detect increased levels of BIM, decreased MCL-1 pro-
tein levels, or increased MCL-1 protein turnover associated with 
steroid sensitization. Instead, we found, by immunoprecipitation 
of endogenous proteins, subcytoxic concentrations of obatoclax 
to result in the disruption of MCL-1 with beclin-1 in ALL cells. 
This suggests the possibility that MCL-1 could control induc-
tion of autophagy via beclin-1, as it was proposed for other BCL-2 
family members recently (14, 15). Interestingly, this effect was not 
seen in cells treated with rapamycin, again pointing out that the 
target mechanism of obatoclax is different. We recognize the fact 
that this effect could also result from indirect mechanisms on the 
protein complex, including MCL-1 and beclin-1. Furthermore, 
functional experiments modulating MCL-1 expression levels were 
not conclusive. Knockdown of MCL-1 resulted in moderate activa-
tion of apoptosis and partial sensitization to dexamethasone that 
was caspase dependent but prevented complete resensitization to 
dexamethasone by obatoclax and autophagic cell death. Activation 
of apoptosis is possibly overriding induction of autophagy in this 
context. In support of this hypothesis, we detected activation of 
caspase-9 after downregulation of MCL-1, with caspase-9–depen-
dent cleavage of beclin-1. This provides a possible mechanism to 
prevent autophagy induction when apoptosis is activated. Taken 
together, steroid modulation with low-dose obatoclax did not 
involve release of proapoptotic BCL-2 family proteins from MCL-1 
but triggered autophagy-dependent cell death by a mechanism 
that required the presence of MCL-1.
In this context, activation of autophagy is required to induce 
necroptosis, a form of programmed necrosis that has been 
described to occur when apoptosis is abortive due to caspase 
inhibition (16, 56). Execution of necroptosis is dependent on the 
RIP-1 kinase (17). Our data demonstrate that RIP-1 activity is 
absolutely required for steroid sensitization by obatoclax and by 
rapamycin. The cell death morphology that was documented by 
electron microscopy is consistent with the morphology reported 
for necroptosis (12, 56). Furthermore, the deubiquitinase cyl-
indromatosis (CYLD), which has been shown to regulate RIP-1 
(38), was functionally required for execution of necroptosis. This 
is consistent with experiments showing that RIP-1 kinase activ-
ity was required to trigger cell death and that ubiquitination of 
RIP-1 prevents cell death signalling (16, 19). RIP-1 and CYLD were 
included among the core genes that were identified in a functional 
siRNA screen for genes that were essential for necroptosis (18). To 
the best of our knowledge, we provide the first clinically relevant 
model with consistent validation in primary leukemia cells from 
patients with very high risk disease, in which the necroptotic path-
way can be exploited to restore response to therapy. As such, this 
will constitute a very relevant experimental model to study the 
mechanisms of necroptosis in depth. Our results clearly imply a 
direct link between the autophagic pathway and RIP-1–mediated 
signalling events leading to necroptosis. Autophagy is triggered 
early and independent of RIP-1 kinase activity, indicating that it 
acts upstream of necroptotic signals. A number of studies identify 
RIP functionally as part of a complex with proteins of the death 
receptor pathway, such as FADD and caspase-8 (35). Experiments 
using mouse models indicate that autophagy and necroptosis 
could be linked via recruitment of components of the death recep-
tor pathway to the membrane of autophagosomes (41). It is tempt-
ing to speculate that a similar mechanism is triggered in ALL cells 
upon costimulation with dexamethasone and obatoclax. Our find-
ings warrant extensive biochemical follow-up studies to under-
stand how RIP-1 is activated and how the autophagic machinery 
is connected to the necroptotic pathway.
Based on promising studies by others (32), we have established 
a leukemia xenograft model of de novo highly resistant ALL. The 
power of this approach resides in the possibility to select cases 
from relevant patient groups, starting from cryopreserved left-
over diagnostic samples, from one of the largest cooperative trials 
for the treatment of childhood ALL. By focusing on cases with 
VHR-ALL by MRD, we also selected for patients that are most 
significantly resistant to prednisone in vivo, as defined by the 
reduction of leukemia cells in the peripheral blood after 1 week 
of prednisone monotherapy. Accordingly, ALL cells from these 
patients were completely resistant to dexamethasone and other 
chemotherapeutic agents in vitro. Low-dose obatoclax restored 
the response to dexamethasone, both in precursor B cell and T cell 
ALL cases. The durable remissions observed with 1 year follow-up, 
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using the leukemia xenograft model, are indicative of strong 
antileukemic activity. Furthermore, the broad chemosensitizing 
effect of low-dose obatoclax in combination with daunorubicin, 
vincristine, and cytarabine in multidrug-resistant primary ALL 
cells provides a strong basis for further evaluation of obatoclax in 
combination with a multidrug regimen. The xenograft approach 
will be essential to validate this approach for heavily pretreated 
relapse and refractory patients. Our observation that isolated 
clones can emerge in clonogenic assays after treatment of a cell 
line with obatoclax and dexamethasone indicates that resistance 
to this approach may occur. Our established xenograft system will 
enable us to screen a larger number of ALL cases to verify whether 
resistance to this approach has to be expected. The identification 
of resistant cases would provide a model to establish markers 
that correlate with response or resistance. Based on current data, 
dynamic changes of mTOR activity with treatment represent a 
good candidate marker. Such knowledge will serve to optimize 
patient selection for clinical trials.
Taken together, our data support a model in which the apop-
totic blockade in GC-resistant ALL cells can be overcome by acti-
vating an autophagy-dependent necroptotic cell death pathway. 
The characteristic necroptotic features by electron microscopy 
and the changes in the phosphorylation profile of S6 protein pro-
vide tools to assess the biological response to combination treat-
ment with obatoclax and dexamethasone in patients in refractory 
ALL. Given the acceptable toxicity profile of obatoclax in clini-
cal studies in adults with hematologic malignancies (9, 10), our 
study provides a compelling rationale for the evaluation of this 
new pharmacological strategy for the treatment of children with 
refractory and relapsed ALL.
Methods
Cell culture, reagents, and standard procedures. CEM-C7-14 and CEM-C1-15 
cells (referred to CEM-C7 and CEM-C1 in the text) were provided by E.B. 
Thompson (University of Texas Medical Branch, Galveston, Texas), human 
hTERT-immortalized primary bone marrow MSCs (57) were provided by 
D. Campana (St Jude Children’s Research Hospital, Memphis, Tennessee), 
caspase-9–deficient and retransfected Jurkat cells (58) as well as Bax/Bak-
deficient Jurkat cells (59) were provided by K. Schulze-Osthoff (Univer-
sity of Tübingen, Germany), and parental and Bax/Bak-deficient MEFs 
(26) were provided by J.-C. Martinou (University of Geneva, Switzerland). 
Rip1–/– cells were provided by B. Seed (Harvard Medical School, Boston, 
Massachusetts). Obatoclax was provided by J. Viallet and G. Shore (Gemin 
X, Malvern, Pennsylvania) and ABT-737 was provided by S. Elmore and S. 
Rosenberg (Abbott Laboratories, Chicago, Illinois).
Detailed procedures are described in Supplemental Methods. For RNA 
silencing experiments, 30 nM beclin-1 (sc-29797, Santa Cruz Biotechnology 
Inc.) was used. pEGFP-LC3 was provided by M. Jäättelä (Danish Cancer Soci-
ety, Copenhagen) and the FLAG-tagged beclin-1 construct by B. Levine (Uni-
versity of Texas Southwestern Medical School, Dallas). All constructs were 
transfected by nucleofection (Amaxa) using solution V and Amaxa program 
T-016 for CEM-C1, A-024 for CEM-C7 cells, and U-020 for MEFs. Transfec-
tion efficiency was controlled using the pEGFP plasmid (Clontech).
Patient samples. ALL cells were recovered from cryopreserved anonymized 
samples from patients who were enrolled in the ongoing ALL-BFM 2000 
protocol and had given informed consent in accordance with the Decla-
ration of Helsinki. Approval was obtained from the Institutional Review 
Board (IRB) of the Medical School Hannover and the local IRB for all par-
ticipating centers in the trial ALL-BFM 2000. This approval extends to the 
use of leftover diagnostic material for add-on research projects, including 
those addressing basic biological questions.
In vitro drug response. In vitro drug response curves in cell lines were 
established with the MTT assay and were normalized to vehicle con-
trol. Primary patient samples were cocultured on hTERT-immortalized 
human MSCs, and drug response curves were analyzed with flow cytom-
etry using propidium iodide.
Xenograft model. Xenograft experiments were approved by the veterinary 
office of the Canton of Zurich. In brief, primary ALL cells were recovered 
from cryopreserved samples and transplanted intrafemorally to NSG mice. 
Leukemia progression was monitored by flow cytometry with human 
CD45 and CD19 antibodies (AbD Serotec). ALL cells recovered from 
spleens of NSG mice after the first xenotransplantation were used for in 
vivo therapeutic trials. Randomized cohorts were treated with vehicle intra-
muscularly (i.m.): 3 mg/kg/d obatoclax i.m., 5 mg/g/d dexamethasone i.p., 
or the combination of dexamethasone i.p. and obatoclax i.m. for 5 days per 
week for 3 consecutive weeks.
Statistics. All experiments were performed 4 times, unless stated otherwise 
in the figure legends. Data are represented as mean ± SD. For in vitro experi-
ments, Student’s t test (2-tailed) was used on triplicates. P values of less than 
0.05 were considered significant. Event-free survival (EFS) was defined as 
the time from the start of treatment until 10% of human leukemia cells were 
detectable in the mouse peripheral blood and was assessed by Kaplan-Meier 
analysis. Survival curves were analyzed with the log-rank test (GraphPad 
prism). P values of less than 0.05 were considered significant.
Acknowledgments
We thank U. Luethi for assistance with electron microscopy and L. 
Walensky, I. Maillard, S. Krishnan, and V. Saha for helpful discus-
sions and feedback on the manuscript. This work was supported 
by grants to J.-P. Bourquin from the Fondation pour la Recherche 
Cancer de l’ Enfant, the Swiss Cancer League, the Swiss National 
Science Foundation, the Foundation for Research at the Medical 
Faculty, University of Zurich, the Julius Müller Foundation, and 
the Huggenberger-Bischoff Foundation.
Received for publication May 26, 2009, and accepted in revised 
form January 6, 2010.
Address correspondence to: Jean-Pierre Bourquin, Department of 
Oncology, University Children’s Hospital Zurich, Steinwiesstrasse 
75, CH-8032 Zurich, Switzerland. Phone: 41.44.266.7304; Fax: 
41.44.266.7171; E-mail: jean-pierre.bourquin@kispi.uzh.ch.
 1. Pui CH, Evans WE. Treatment of acute lymphoblas-
tic leukemia. N Engl J Med. 2006;354(2):166–178.
 2. Schrappe M. Evolution of BFM trials for childhood 
ALL. Ann Hematol. 2004;83(Suppl 1):S121–S123.
 3. Schrauder A, et al. Prospective evaluation of MRD–
Kinetics in 274 children with high-risk ALL treated 
in trial ALL–BFM 2000: Insights into develop-
ment of resistance and impact on further refine-
ment of treatment stratification strategies. Blood. 
2007;110:585.
 4. Holleman A, et al. Gene-expression patterns in 
drug-resistant acute lymphoblastic leukemia 
cells and response to treatment. N Engl J Med. 
2004;351(6):533–542.
 5. Wei G, et al. Gene expression-based chemical 
genomics identifies rapamycin as a modulator of 
MCL1 and glucocorticoid resistance. Cancer Cell. 
2006;10(4):331–342.
 6. Nguyen M, et al. Small molecule obatoclax (GX15-
070) antagonizes MCL-1 and overcomes MCL-1-
mediated resistance to apoptosis. Proc Natl Acad Sci 
U S A. 2007;104(49):19512–19517.
 7. Perez-Galan P, Roue G, Villamor N, Campo E, 
Colomer D. The BH3-mimetic GX15-070 syner-
gizes with bortezomib in mantle cell lymphoma by 
enhancing Noxa-mediated activation of Bak. Blood. 
2007;109(10):4441–4449.
 8. Konopleva M, et al. Mechanisms of antileukemic 
activity of the novel Bcl-2 homology domain-3 
mimetic GX15-070 (obatoclax). Cancer Res. 2008; 
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 4   April 2010 1323
68(9):3413–3420.
 9. O’Brien SM, et al. Phase I study of obatoclax mesyl-
ate (GX15-070), a small molecule pan-Bcl-2 family 
antagonist, in patients with advanced chronic lym-
phocytic leukemia. Blood. 2009;113(2):299–305.
 10. Schimmer AD, et al. A phase I study of the pan bcl-
2 family inhibitor obatoclax mesylate in patients 
with advanced hematologic malignancies. Clin Can-
cer Res. 2008;14(24):8295–8301.
 11. Shimizu S, et al. Role of Bcl-2 family proteins 
in a non-apoptotic programmed cell death 
dependent on autophagy genes. Nat Cell Biol. 
2004;6(12):1221–1228.
 12. Yu L, et al. Regulation of an ATG7-beclin 1 pro-
gram of autophagic cell death by caspase-8. Science. 
2004;304(5676):1500–1502.
 13. Kroemer G, Levine B. Autophagic cell death: 
the story of a misnomer. Nat Rev Mol Cell Biol. 
2008;9(12):1004–1010.
 14. Maiuri MC, et al. Functional and physical interac-
tion between Bcl-X(L) and a BH3-like domain in 
Beclin-1. EMBO J. 2007;26(10):2527–2539.
 15. Pattingre S, et al. Bcl-2 antiapoptotic proteins 
inhibit Beclin 1-dependent autophagy. Cell. 
2005;122(6):927–939.
 16. Holler N, et al. Fas triggers an alternative, cas-
pase-8-independent cell death pathway using 
the kinase RIP as effector molecule. Nat Immunol. 
2000;1(6):489–495.
 17. Degterev A, et al. Identification of RIP1 kinase as 
a specific cellular target of necrostatins. Nat Chem 
Biol. 2008;4(5):313–321.
 18. Hitomi J, et al. Identification of a molecular signal-
ing network that regulates a cellular necrotic cell 
death pathway. Cell. 2008;135(7):1311–1323.
 19. O’Donnell MA, Legarda-Addison D, Skountzos P, 
Yeh WC, Ting AT. Ubiquitination of RIP1 regulates 
an NF-kappaB-independent cell-death switch in 
TNF signaling. Curr Biol. 2007;17(5):418–424.
 20. Oltersdorf T, et al. An inhibitor of Bcl-2 family pro-
teins induces regression of solid tumours. Nature. 
2005;435(7042):677–681.
 21. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp 
M, Letai A. BH3 profiling identifies three distinct 
classes of apoptotic blocks to predict response 
to ABT-737 and conventional chemotherapeutic 
agents. Cancer Cell. 2007;12(2):171–185.
 22. Konopleva M, et al. Mechanisms of apoptosis 
sensitivity and resistance to the BH3 mimetic 
ABT-737 in acute myeloid leukemia. Cancer Cell. 
2006;10(5):375–388.
 23. van Delft MF, et al. The BH3 mimetic ABT-737 tar-
gets selective Bcl-2 proteins and efficiently induces 
apoptosis via Bak/Bax if Mcl-1 is neutralized.  
Cancer Cell. 2006;10(5):389–399.
 24. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic 
and autophagic cell death induced by histone 
deacetylase inhibitors. Proc Natl Acad Sci U S A. 
2004;101(52):18030–18035.
 25. Luo S, Rubinsztein DC. Atg5 and Bcl-2 provide novel 
insights into the interplay between apoptosis and 
autophagy. Cell Death Differ. 2007;14(7):1247–1250.
 26. Lindsten T, et al. The combined functions of pro-
apoptotic Bcl-2 family members bak and bax are 
essential for normal development of multiple tissues. 
Mol Cell. 2000;6(6):1389–1399.
 27. Sarbassov DD, Ali SM, Sabatini DM. Growing 
roles for the mTOR pathway. Curr Opin Cell Biol. 
2005;17(6):596–603.
 28. Wang H, Kubica N, Ellisen LW, Jefferson LS, 
Kimball SR. Dexamethasone represses signaling 
through the mammalian target of rapamycin in 
muscle cells by enhancing expression of REDD1. 
J Biol Chem. 2006;281(51):39128–39134.
 29. Certo M, et al. Mitochondria primed by death signals 
determine cellular addiction to antiapoptotic BCL-2 
family members. Cancer Cell. 2006;9(5):351–365.
 30. Chen L, et al. Differential targeting of prosurvival 
Bcl-2 proteins by their BH3-only ligands allows 
complementary apoptotic function. Mol Cell. 
2005;17(3):393–403.
 31. Maurer U, Charvet C, Wagman AS, Dejardin E, 
Green DR. Glycogen synthase kinase-3 regulates 
mitochondrial outer membrane permeabilization 
and apoptosis by destabilization of MCL-1. Mol 
Cell. 2006;21(6):749–760.
 32. Bachmann PS, Gorman R, Mackenzie KL, Lutze-
Mann L, Lock RB. Dexamethasone resistance in 
B-cell precursor childhood acute lymphoblastic 
leukemia occurs downstream of ligand-induced 
nuclear translocation of the glucocorticoid receptor. 
Blood. 2005;105(6):2519–2526.
 33. Fakler M, et al. Small molecule XIAP inhibitors 
cooperate with TRAIL to induce apoptosis in child-
hood acute leukemia cells and overcome Bcl-2-medi-
ated resistance. Blood. 2009;113(8):1710–1722.
 34. Miao B, Degterev A. Methods to analyze cellular 
necroptosis. Methods Mol Biol. 2009;559:79–93.
 35. Declercq W, Vanden Berghe T, Vandenabeele P. RIP 
kinases at the crossroads of cell death and survival. 
Cell. 2009;138(2):229–232.
 36. Galluzzi L, Kroemer G. Necroptosis: a special-
ized pathway of programmed necrosis. Cell. 
2008;135(7):1161–1163.
 37. Ting AT, Pimentel-Muinos FX, Seed B. RIP medi-
ates tumor necrosis factor receptor 1 activation of 
NF-kappaB but not Fas/APO-1-initiated apoptosis. 
EMBO J. 1996;15(22):6189–6196.
 38. Wright A, et al. Regulation of early wave of germ cell 
apoptosis and spermatogenesis by deubiquitinating 
enzyme CYLD. Dev Cell. 2007;13(5):705–716.
 39. Shultz LD, et al. Human lymphoid and myeloid cell 
development in NOD/LtSz-scid IL2R gamma null 
mice engrafted with mobilized human hemopoietic 
stem cells. J Immunol. 2005;174(10):6477–6489.
 40. Matsunaga T, et al. Regulation of annexin II by 
cytokine-initiated signaling pathways and E2A-
HLF oncoprotein. Blood. 2004;103(8):3185–3191.
 41. Bell BD, et al. FADD and caspase-8 control the out-
come of autophagic signaling in proliferating T cells. 
Proc Natl Acad Sci U S A. 2008;105(43):16677–16682.
 42. Qu X, et al. Promotion of tumorigenesis by 
heterozygous disruption of the beclin 1 autophagy 
gene. J Clin Invest. 2003;112(12):1809–1820.
 43. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an 
autophagy gene essential for early embryonic devel-
opment, is a haploinsufficient tumor suppressor. 
Proc Natl Acad Sci U S A. 2003;100(25):15077–15082.
 44. Levine B, Kroemer G. Autophagy in the pathogen-
esis of disease. Cell. 2008;132(1):27–42.
 45. Koike M, et al. Inhibition of autophagy pre-
vents hippocampal pyramidal neuron death 
after hypoxic-ischemic injury. Am J Pathol. 
2008;172(2):454–469.
 46. Salazar M, et al. Cannabinoid action induces 
autophagy-mediated cell death through stimula-
tion of ER stress in human glioma cells. J Clin Invest. 
2009;119(5):1359–1372.
 47. Berry DL, Baehrecke EH. Growth arrest and autoph-
agy are required for salivary gland cell degradation 
in Drosophila. Cell. 2007;131(6):1137–1148.
 48. Denton D, et al. Autophagy, not apoptosis, is essen-
tial for midgut cell death in Drosophila. Curr Biol. 
2009;19(20):1741–1746.
 49. Laane E, et al. Cell death induced by dexa-
methasone in lymphoid leukemia is mediated 
through initiation of autophagy. Cell Death Differ. 
2009;16(7):1018–1029.
 50. Bornhauser BC, et al. Low dose arsenic trioxide sen-
sitizes glucocorticoid-resistant acute lymphoblastic 
leukemia cells to dexamethasone via an Akt-depen-
dent pathway. Blood. 2007;110(6):2084–2091.
 51. Guertin DA, Sabatini DM. Defining the role of 
mTOR in cancer. Cancer Cell. 2007;12(1):9–22.
 52. Wang Z, Malone MH, Thomenius MJ, Zhong F, Xu 
F, Distelhorst CW. Dexamethasone-induced gene 
2 (dig2) is a novel pro-survival stress gene induced 
rapidly by diverse apoptotic signals. J Biol Chem. 
2003;278(29):27053–27058.
 53. Balgi AD, et al. Screen for chemical modulators of 
autophagy reveals novel therapeutic inhibitors of 
mTORC1 signaling. PLoS ONE. 2009;4(9):e7124.
 54. Bachmann PS, et al. Divergent mechanisms of 
glucocorticoid resistance in experimental models 
of pediatric acute lymphoblastic leukemia. Cancer 
Res. 2007;67(9):4482–4490.
 55. Tissing WJ, et al. Glucocorticoid-induced gluco-
corticoid-receptor expression and promoter usage 
is not linked to glucocorticoid resistance in child-
hood ALL. Blood. 2006;108(3):1045–1049.
 56. Degterev A, et al. Chemical inhibitor of nonapoptot-
ic cell death with therapeutic potential for ischemic 
brain injury. Nat Chem Biol. 2005;1(2):112–119.
 57. Iwamoto S, Mihara K, Downing JR, Pui CH, Cam-
pana D. Mesenchymal cells regulate the response of 
acute lymphoblastic leukemia cells to asparaginase. 
J Clin Invest. 2007;117(4):1049–1057.
 58. Janssen K, Pohlmann S, Janicke RU, Schulze-
Osthoff K, Fischer U. Apaf-1 and caspase-9 deficien-
cy prevents apoptosis in a Bax-controlled pathway 
and promotes clonogenic survival during paclitaxel 
treatment. Blood. 2007;110(10):3662–3672.
 59. Samraj AK, Stroh C, Fischer U, Schulze-Osthoff K. 
The tyrosine kinase Lck is a positive regulator of the 
mitochondrial apoptosis pathway by controlling 
Bak expression. Oncogene. 2006;25(2):186–197.
